<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03157583</url>
  </required_header>
  <id_info>
    <org_study_id>207583</org_study_id>
    <nct_id>NCT03157583</nct_id>
  </id_info>
  <brief_title>A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations</brief_title>
  <official_title>Determination of the Sun Protection Factor (SPF) and in Vitro UVA Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the SPF and UVAPF of four sunscreen formulations
      using international standard methodologies ISO24444:2010 for SPF and ISO24443:2012 for UVAPF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consist of two steps. Step 1: determination of the SPF of the test products which
      will be performed as a single-center, randomized, evaluator blind, intra-individual
      comparison, no treatment and positive controlled clinical study as per ISO24444:2010. And
      Step 2: determination of the UVAPF of the test products which will be performed as a single
      center, open-label, negative and positive controlled technical test as per ISO24443:2012
      (using test plates for assessing UV transmittance of four developmental sunscreens).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Actual">July 7, 2017</completion_date>
  <primary_completion_date type="Actual">July 7, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values</measure>
    <time_frame>Up to 24 hours post UV exposure</time_frame>
    <description>Arithmetic mean of all valid SPFi values of each product on each participant was calculated from the individual Minimal Erythemal Dose (MED) on product treated (MEDp) test sites in relation to unprotected (MEDu) test sites 16-24 hours after exposure to ultraviolet (UV) radiation. SPFi = MEDp/MEDu. No inferential statistical analysis was performed for this outcome.The provisional MEDu was the lowest dose of UV radiation that produces the first perceptible unambiguous erythema with defined borders appearing over most of the field of UV exposure.Higher values represents increased SPF protection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spectrum of Sun Protection</measure>
    <time_frame>Up to 30 minutes post UV exposure</time_frame>
    <description>Broad spectrum of sun protection was calculated by the ratio of the arithmetic mean of SPF to the arithmetic mean of UVAPF. Higher values represents increased SPF protection.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Sunscreening Agents</condition>
  <arm_group>
    <arm_group_label>Reference product (for SPFi calculation)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will include all the test sites on the participants back where reference product (P3 standard sunscreen) will be applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test product 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 1 will be applied for SPF testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test product 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 2 will be applied for SPF testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test product 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 3 will be applied for SPF testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test product 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 4 will be applied for SPF testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative control (for SPFi calculation)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will include all the test sites on the participants back which will be left unprotected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference (for UVAPFi calculation)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will include test plates treated with reference sunscreen formulation S2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blank control (for UVAPFi calculation)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm will include blank test plates treated with glycerin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NGBUV000A, (Expected SPF 30)</intervention_name>
    <description>A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.</description>
    <arm_group_label>Test product 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NGBUV000B, (Expected SPF 30)</intervention_name>
    <description>A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.</description>
    <arm_group_label>Test product 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NGBUV000C, (Expected SPF 30)</intervention_name>
    <description>A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.</description>
    <arm_group_label>Test product 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NGBUV000D, (Expected SPF 30)</intervention_name>
    <description>A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.</description>
    <arm_group_label>Test product 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3 Standard, (Expected SPF 16)</intervention_name>
    <description>A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.</description>
    <arm_group_label>Reference product (for SPFi calculation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sunscreen formulation S2</intervention_name>
    <description>A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.</description>
    <arm_group_label>Reference (for UVAPFi calculation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glycerin</intervention_name>
    <description>A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.</description>
    <arm_group_label>Blank control (for UVAPFi calculation)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Demonstrates understanding of the study procedures, restrictions and willingness to
             participate as evidenced by voluntary written informed consent and has received a
             signed and dated copy of the informed consent form

          -  Good general and mental health with, in the opinion of the investigator or medically
             qualified designee no clinically significant and relevant abnormalities in medical
             history or upon physical examination

          -  Participants with a Fitzpatrick Skin Type of I, II or III

          -  Participants with an Individual Typology Angle (ITA°) greater than 28°

        Exclusion Criteria:

          -  Women who are known to be pregnant or who are intending to become pregnant over the
             duration of the study

          -  Women who are breast-feeding or lactating

          -  Participants having used medication with known photo-toxic and/or photosensitizing
             potential (e.g. hypericum perforatum, antibiotics, blood pressure regulating agents)
             up to 14 days prior to screening

          -  Participants with a history of systemic therapy with anti-inflammatory agents or
             analgesics (e.g. diclofenac) up to 3 days prior to screening

          -  Participants with dermatological conditions

          -  Participants with a history of abnormal response to the sun

          -  Participants having marks, blemishes or nevi or presenting existing sun damage in the
             test area

          -  Participants having excessive hair, moles, tattoos, scars or other imperfections in
             the test area that could influence the investigation

          -  Participants with a history of systemic therapy with immuno-suppressive drugs (e.g.
             corticosteroids) and/or antihistamines (e.g. anti-allergics) up to 7 days prior to
             screening

          -  Participants with a non-uniform skin colour or hyperpigmentation in the test area

          -  Participants with a medical history of dysplastic nevi or melanoma

          -  Participants with one of the following illnesses that might require regular systemic
             medication: Insulin-dependent diabetes, cancer

          -  Participants with asthma, unless medicated

          -  Participants with an electronic implant (e.g. pace maker, insulin pump, hearing aid)
             that cannot be removed during irradiation

          -  AIDS (acquired immune deficiency syndrome) and infectious hepatitis, if known to the
             participants

          -  Known or suspected intolerance or hypersensitivity to the study materials (or closely
             related compounds) or any of their stated ingredients

          -  Known allergy to latex

          -  Participation in another clinical study (including cosmetic studies) or receipt of an
             investigational drug within 30 days prior to screening

          -  Participation in another clinical study involving UV exposure to the same test site up
             to 2 months prior to screening

          -  Previous participation in this study

          -  Recent history (within the last 5 years) of alcohol or other substance abuse

          -  Participants who have used a tanning bed or other tanning treatment on the back area
             up to 1 month prior to screening

          -  Participants accustomed to using tanning beds

          -  Participants who have used self-tanning products on the back area in the previous 1
             month prior to screening

          -  An employee of the sponsor or the study site or members of their immediate family
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schenefeld</city>
        <state>Schleswig-Holstein</state>
        <zip>22869</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <results_first_submitted>June 15, 2018</results_first_submitted>
  <results_first_submitted_qc>May 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2019</results_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunscreening Agents</mesh_term>
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03157583/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03157583/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All the participants were enrolled at one center in Germany.</recruitment_details>
      <pre_assignment_details>Total of 9 participants were screened for the study out of which 1 participant did not meet the study criteria. Remaining 8 participants were randomized in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All the participants randomized to the study. In this study, there were a total of 7 test sites assigned to each participant. One test site was used for provisional MEDu (Minimal Erythemal Dose of Unprotected Skin) measurement, on the remaining 6 sites test products (4) and the positive control product (P3 standard) were applied and 1 site was left unprotected.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other (did not meet study criteria)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline parameters were reported for safety population (N=8). The Safety population included all participants who applied any of the study products.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Included all the participants who randomized to receive the study product.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" spread="18.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values</title>
        <description>Arithmetic mean of all valid SPFi values of each product on each participant was calculated from the individual Minimal Erythemal Dose (MED) on product treated (MEDp) test sites in relation to unprotected (MEDu) test sites 16-24 hours after exposure to ultraviolet (UV) radiation. SPFi = MEDp/MEDu. No inferential statistical analysis was performed for this outcome.The provisional MEDu was the lowest dose of UV radiation that produces the first perceptible unambiguous erythema with defined borders appearing over most of the field of UV exposure.Higher values represents increased SPF protection.</description>
        <time_frame>Up to 24 hours post UV exposure</time_frame>
        <population>Analysis population included all randomized participants who underwent irradiation at Visit 4. Here, number analyzed signifies participants with available data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product 1</title>
            <description>This arm included all the test sites on the participants back where test product 1 was applied for SPF testing.</description>
          </group>
          <group group_id="O2">
            <title>Test Product 2</title>
            <description>This arm included all the test sites on the participants back where test product 2 was applied for SPF testing.</description>
          </group>
          <group group_id="O3">
            <title>Test Product 3</title>
            <description>This arm included all the test sites on the participants back where test product 3 was applied for SPF testing.</description>
          </group>
          <group group_id="O4">
            <title>Test Product 4</title>
            <description>This arm included all the test sites on the participants back where test product 4 was applied for SPF testing.</description>
          </group>
          <group group_id="O5">
            <title>Reference Product (for SPFi Calculation)</title>
            <description>This arm included all the test sites on the participants back where reference product (P3 standard sunscreen) was applied.</description>
          </group>
        </group_list>
        <measure>
          <title>Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values</title>
          <description>Arithmetic mean of all valid SPFi values of each product on each participant was calculated from the individual Minimal Erythemal Dose (MED) on product treated (MEDp) test sites in relation to unprotected (MEDu) test sites 16-24 hours after exposure to ultraviolet (UV) radiation. SPFi = MEDp/MEDu. No inferential statistical analysis was performed for this outcome.The provisional MEDu was the lowest dose of UV radiation that produces the first perceptible unambiguous erythema with defined borders appearing over most of the field of UV exposure.Higher values represents increased SPF protection.</description>
          <population>Analysis population included all randomized participants who underwent irradiation at Visit 4. Here, number analyzed signifies participants with available data for this outcome measure.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" lower_limit="26.08" upper_limit="40.22"/>
                    <measurement group_id="O2" value="35.2" lower_limit="25.85" upper_limit="44.42"/>
                    <measurement group_id="O3" value="35.2" lower_limit="26.82" upper_limit="43.68"/>
                    <measurement group_id="O4" value="45.2" lower_limit="38.80" upper_limit="51.58"/>
                    <measurement group_id="O5" value="15.6" lower_limit="12.66" upper_limit="18.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spectrum of Sun Protection</title>
        <description>Broad spectrum of sun protection was calculated by the ratio of the arithmetic mean of SPF to the arithmetic mean of UVAPF. Higher values represents increased SPF protection.</description>
        <time_frame>Up to 30 minutes post UV exposure</time_frame>
        <population>Analysis population included all randomized participants who underwent irradiation at Visit 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product 1</title>
            <description>This arm included all the test plates used for UVAPF testing and test sites on the participants back where test product 1 was applied for SPF testing.</description>
          </group>
          <group group_id="O2">
            <title>Test Product 2</title>
            <description>This arm included all the test plates used for UVAPF testing and test sites on the participants back where test product 2 was applied for SPF testing.</description>
          </group>
          <group group_id="O3">
            <title>Test Product 3</title>
            <description>This arm included all the test plates used for UVAPF testing and test sites on the participants back where test product 3 was applied for SPF testing.</description>
          </group>
          <group group_id="O4">
            <title>Test Product 4</title>
            <description>This arm included all the test plates used for UVAPF testing and test sites on the participants back where test product 4 was applied for SPF testing.</description>
          </group>
          <group group_id="O5">
            <title>Reference (for UVAPFi and SPFi Calculation)</title>
            <description>This arm included test plates treated with reference sunscreen formulation S2. Also includes all the test sites on the participants back where reference product (P3 standard sunscreen) was applied.</description>
          </group>
        </group_list>
        <measure>
          <title>Spectrum of Sun Protection</title>
          <description>Broad spectrum of sun protection was calculated by the ratio of the arithmetic mean of SPF to the arithmetic mean of UVAPF. Higher values represents increased SPF protection.</description>
          <population>Analysis population included all randomized participants who underwent irradiation at Visit 4.</population>
          <units>Ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11"/>
                    <measurement group_id="O2" value="2.98"/>
                    <measurement group_id="O3" value="2.88"/>
                    <measurement group_id="O4" value="2.95"/>
                    <measurement group_id="O5" value="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 16 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Reference Product (for SPFi Calculation)</title>
          <description>This arm included all the test sites on the participants back where reference product (P3 standard sunscreen) was applied.</description>
        </group>
        <group group_id="E2">
          <title>Negative Control (for SPFi Calculation)</title>
          <description>This arm included all the test sites on the participants back which were left unprotected.</description>
        </group>
        <group group_id="E3">
          <title>Test Product 1</title>
          <description>This arm included all the test sites on the participants back where test product 1 was applied for SPF testing.</description>
        </group>
        <group group_id="E4">
          <title>Test Product 2</title>
          <description>This arm included all the test sites on the participants back where test product 2 was applied for SPF testing.</description>
        </group>
        <group group_id="E5">
          <title>Test Product 3</title>
          <description>This arm included all the test sites on the participants back where test product 3 was applied for SPF testing.</description>
        </group>
        <group group_id="E6">
          <title>Test Product 4</title>
          <description>This arm included all the test sites on the participants back where test product 4 was applied for SPF testing.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

